BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1009527)

  • 1. PHASE I clinical trial of an oral solution of VP-16-213.
    Nissen NI; Dombernowsky P; Hansen HH; Larsen V
    Cancer Treat Rep; 1976 Jul; 60(7):943-5. PubMed ID: 1009527
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
    Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract]   [Full Text] [Related]  

  • 4. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
    Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Etoposide: VP-16].
    Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1982; 119(2):15-8. PubMed ID: 7160031
    [No Abstract]   [Full Text] [Related]  

  • 6. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
    Anderson G; Payne H
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VP-16-213 (etoposide) in the management of germinal testis tumors.
    Pizzocaro G
    Prog Clin Biol Res; 1985; 203():391-400. PubMed ID: 2421333
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
    Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
    Van Echo DA; Wiernik PH; Aisner J
    Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of etoposide in advanced prostate cancer.
    Trump DL; Loprinzi CL
    Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
    Kelsen DP; Magill GB; Cheng E; Dukeman M; Sordillo P; Heelan R; Yagoda A
    Cancer Treat Rep; 1983 May; 67(5):509-10. PubMed ID: 6850667
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of VP-16-213 in non-small-cell lung cancer.
    Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
    Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
    Suzuki K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
    Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T
    Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of etoposide for carcinoma of the prostate.
    Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
    [No Abstract]   [Full Text] [Related]  

  • 17. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 18. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospects of new chemotherapies].
    Sculier JP; Klastersky J
    Rev Med Brux; 1982 Oct; 3(8):519-27. PubMed ID: 6897459
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.